IFIH1 and dermatomyositis: Although a strategy of early detection and potent combination immunosuppressive therapy (high-dose glucocorticoid, cyclosporine, and intravenous cyclophosphamide pulse) can improve the survival rate of anti-MDA5 Ab+ DM patients, the mortality rate remains high at 25% even with triple therapy.[2]